Development of anti-obesity agents: drugs that target neuropeptide and neurotransmitter systems

Bibliography

• Parker E, Van Heek M, Stamford A. Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status. Eur J Pharmacol 2002;440:173-87
   PubMed Web of Science ®Google Scholar
• MacNeil DJ, Kanatani A. NPY and energy homeostasis: an opportunity for novel anti-obesity therapies. EXS 2006;95:143-56
   PubMedGoogle Scholar
• Ishihara A, Kanatani A, Mashiko S, et al. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice. Proc Natl Acad Sci USA 2006;103:7154-8
   PubMed Web of Science ®Google Scholar
• Erondu N, Gantz I, Musser B, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006;4:275-82
   PubMed Web of Science ®Google Scholar
• Greenberg I, Kuehnle J, Medelson J, Bernstein J. Effects of marijuana use on body weight and caloric intake in humans. Psychopharmacology 1976;49:79-84
   PubMed Web of Science ®Google Scholar
• Hollister LE. Hunger and appetite after single doses of marihuana, alcohol, and dextroamphetamine. Clin Pharmacol Ther 1971;12:44-9
   PubMed Web of Science ®Google Scholar
• Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10:89-97
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822-5
   PubMed Web of Science ®Google Scholar
• Arnone M, Maruani J, Chaperon F, et al. Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 1997;132:104-6
   PubMed Web of Science ®Google Scholar
• Colombo G, Agabio R, Diaz G, et al. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 1998;63:113-7
   Web of Science ®Google Scholar
• Bouaboula M, Perrachon S, Milligan L, et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 1997;272:22330-9
   PubMed Web of Science ®Google Scholar
• Lin LS, Lanza TJ Jr, Jewell JP, et al. Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem 2006;49:7584-7
   PubMed Web of Science ®Google Scholar
• Fong TM, Guan X-M, Marsh DJ, et al. Anti-obesity efficacy of a novel cannabinoid-1 receptor inverse agonist MK-0364 in rodents. J Pharmacol Exp Ther 2007;321:1013-22
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97
   PubMed Web of Science ®Google Scholar
• Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-72
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75
   PubMed Web of Science ®Google Scholar
• Stevens C, Cilisssen C, Desmet M, et al. MK-0364, a CB1R inverse agonist, reduces acute food intake in overweight/obese male volunteers. Diabetes 2007;56(Suppl 1):A462
   Google Scholar
• Blundell JE, Jebb SA, Stiubbs RJ, et al. Effcet of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet: the REBA study. Obes Rev 2006;7(Suppl 2):104
   Google Scholar
• Addy C, Wright H, Van Laere K, et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 2008;7:68-78
   PubMed Web of Science ®Google Scholar
• Burns HD, Van Laere K, Sanabria-Bohorquez S, et al. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA 2007;104:9800-5
   PubMed Web of Science ®Google Scholar
• Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63:908-14
   PubMed Web of Science ®Google Scholar
• Lofgren P, Sjolin E, Wahlen K, Hoffstedt J. Human adipose tissue cannabinoid receptor 1 gene expression is not related to fat cell function or adiponectin level. J Clin Endocrinol Metab 2007;92:1555-9
   PubMed Web of Science ®Google Scholar
• Hamilton B, Allgaeuer S, Getta P, et al. Do adipose tissue cannabinoid CB1 receptor modulate adiponectin expression or lipolysis? Obes Res 2005;13(2005 NAASO Program Abstract Suppl):A162
   Google Scholar
• Marsh DJ, Hollopeter G, Huszar D, et al. Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat Genet 1999;21:119-22
   PubMed Web of Science ®Google Scholar
• Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418:650-4
   Google Scholar
• Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005;129:1430-6
   PubMed Web of Science ®Google Scholar
• Tschop M, Castaneda TR, Joost HG, et al. Does gut hormone PYY3-36 decrease food intake in rodents? Nature 2004;430:166-8
   Google Scholar
• Kuo LE, Kitlinska JB, Tilan JU, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007;13:803-11
   PubMed Web of Science ®Google Scholar
• Gantz I, Erondu N, Mallick M, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007;92:1754-7
   PubMed Web of Science ®Google Scholar
• Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004;56:3-17
   Google Scholar
• Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 2007;337:1-24
   PubMed Web of Science ®Google Scholar
• Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 1973;84:488-95
   Google Scholar
• Stacher G, Steinringer H, Schmierer G, et al. Cholecystokinin octapeptide decreases intake of solid food in man. Peptides 1982;3:133-6
   PubMed Web of Science ®Google Scholar
• West DB, Fey D, Woods SC. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol 1984;246:R776-87
   PubMed Web of Science ®Google Scholar
• Jordan J, Greenway FL, Leiter LA, et al. Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Mol Ther 2008;83:281-7
   Google Scholar
• Castillo EJ, Delgado-Aros S, Camilleri M, et al. Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2004;287:G363-9
   PubMed Web of Science ®Google Scholar
• Bjening C, Williams J, Whelan K, et al. Chronic oral administration of APD356 significantly reduces body weight and fat mass in obesity-prone male and female rats. Int J Obesity 2004;28(1 Suppl):214s
   Google Scholar
• Smith S, Prosser W, Donahue D, et al. APD356, an orally-active selective 5HT2c agonist, reduces body weight in obese adult men and women. Diabetes 2006;55(Suppl 1):344-OR
   Web of Science ®Google Scholar
• Hopkins PN, Polukoff GI. Risk of valvular heart disease associated with use of fenfluramine. BMC Cardiovasc Disord 2003;3:5-18
   PubMed Web of Science ®Google Scholar